Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer

Programmed death ligand 1 (PD-L1) immune checkpoint inhibitors are promising therapeutic agents for treating cancers but the response rate is <20%. Some chemotherapeutic drugs could also activate an anticancer immune response to kill cancer cells, apart from their direct cytotoxicity. Our study i...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Min, Wang, Fang, Zhang, Hong, To, Kenneth K. W., Wu, Shaocong, Chen, Zhen, Liang, Shaobo, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452895/
https://www.ncbi.nlm.nih.gov/pubmed/32855386
http://dx.doi.org/10.1038/s41392-020-0200-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452895/
https://www.ncbi.nlm.nih.gov/pubmed/32855386
http://dx.doi.org/10.1038/s41392-020-0200-4

Ejemplares similares